US FDA approves Eli Lilly's therapy for metastatic breast cancer-March 2024-www.financetom.com

US FDA approves Eli Lilly's therapy for metastatic breast cancer

News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities

US FDA approves Eli Lilly's therapy for metastatic breast cancer

Sep 25, 2025 11:20 AM

Sept 25 (Reuters) - Eli Lilly ( LLY ) said on Thursday

that the U.S. Food and Drug Administration has approved its

therapy for the treatment of metastatic breast cancer in

patients whose disease progressed after at least one line of

endocrine therapy.

Previous page： Sula Vineyards expects bumper harvest in early 2024 Next page： Axis Mutual Fund eyes ₹3 lakh crore AUM by March, expects ₹2,500 crore from new fund

Comments

Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.

Show More Comments

Related Articles >

Sula Vineyards expects bumper harvest in early 2024

Nov 29, 2023

The unseasonal rainfall in Mumbai and other parts of the state prompted concerns about potential disruptions in the agricultural supply chain.

Axis Mutual Fund eyes ₹3 lakh crore AUM by March, expects ₹2,500 crore from new fund

Nov 29, 2023

The fund house opened the year with an AUM (assets under management) of over ₹2.25 lakh crore. The open-ended equity scheme represents the manufacturing theme and opens for subscription on December 1 and closes on December 15.

Cult US sneaker brand Foot Locker inks exclusive licensing deal with Metro Brands & Nykaa

Nov 29, 2023

The volume of the sneaker segment in India is projected to reach 66 million pairs by 2028. Shares of Metro Brands Ltd ended at ₹1,326.85, up by ₹27.10, or 2.09%, and shares of FSN E-Commerce Ventures Ltd ended at ₹172.10, up by ₹2.80, or 1.65%, on the BSE.

UltraTech Cement acquires Burnpur Cement's grinding assets in Jharkhand for ₹170 crore

Nov 29, 2023

This acquisition not only substantially hikes UltraTech Cement's capacity but also serves as a strategic entry into the promising market of Jharkhand. Shares of UltraTech Cement Ltd ended at ₹8,721.80, down by ₹6.20, or 0.071%, on the BSE.